Avalo Therapeutics Inc
NASDAQ:AVTX
Balance Sheet
Balance Sheet Decomposition
Avalo Therapeutics Inc
Avalo Therapeutics Inc
Balance Sheet
Avalo Therapeutics Inc
| Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
1
|
10
|
3
|
12
|
21
|
5
|
2
|
11
|
4
|
19
|
55
|
13
|
7
|
135
|
|
| Cash Equivalents |
1
|
10
|
3
|
12
|
21
|
5
|
2
|
11
|
4
|
19
|
55
|
13
|
7
|
135
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
8
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
7
|
6
|
5
|
4
|
5
|
2
|
0
|
1
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
1
|
1
|
2
|
1
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
4
|
5
|
4
|
2
|
4
|
2
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
1
|
0
|
0
|
0
|
1
|
5
|
1
|
3
|
2
|
1
|
1
|
4
|
|
| Total Current Assets |
1
|
10
|
4
|
12
|
22
|
6
|
11
|
22
|
18
|
26
|
62
|
16
|
8
|
139
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
3
|
2
|
2
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
3
|
2
|
2
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
18
|
4
|
2
|
2
|
0
|
0
|
0
|
0
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
14
|
14
|
14
|
14
|
14
|
14
|
11
|
11
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
30
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
14
|
14
|
14
|
14
|
14
|
14
|
11
|
11
|
|
| Total Assets |
1
N/A
|
10
+677%
|
5
-49%
|
12
+143%
|
22
+76%
|
6
-73%
|
43
+642%
|
70
+64%
|
36
-49%
|
44
+21%
|
80
+83%
|
33
-58%
|
21
-37%
|
151
+618%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
0
|
1
|
2
|
1
|
1
|
1
|
1
|
1
|
2
|
3
|
3
|
3
|
0
|
0
|
|
| Accrued Liabilities |
0
|
1
|
1
|
1
|
2
|
1
|
7
|
5
|
6
|
11
|
16
|
13
|
4
|
6
|
|
| Short-Term Debt |
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
2
|
3
|
2
|
0
|
0
|
0
|
0
|
0
|
6
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
1
|
0
|
0
|
3
|
19
|
5
|
1
|
0
|
1
|
0
|
0
|
|
| Total Current Liabilities |
4
|
2
|
3
|
5
|
6
|
4
|
11
|
26
|
12
|
15
|
20
|
22
|
5
|
7
|
|
| Long-Term Debt |
0
|
0
|
0
|
5
|
2
|
0
|
0
|
0
|
0
|
0
|
33
|
13
|
2
|
2
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
4
|
23
|
3
|
4
|
4
|
9
|
7
|
8
|
|
| Total Liabilities |
4
N/A
|
2
-59%
|
3
+99%
|
10
+236%
|
9
-17%
|
6
-35%
|
15
+169%
|
49
+230%
|
15
-69%
|
19
+27%
|
57
+198%
|
44
-22%
|
14
-69%
|
18
+29%
|
|
| Equity | |||||||||||||||
| Common Stock |
0
|
20
|
20
|
28
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
3
|
14
|
27
|
43
|
54
|
70
|
58
|
98
|
114
|
178
|
262
|
304
|
335
|
370
|
|
| Additional Paid In Capital |
1
|
3
|
9
|
17
|
67
|
70
|
83
|
119
|
135
|
202
|
285
|
293
|
342
|
503
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
2
N/A
|
8
N/A
|
2
-76%
|
2
N/A
|
13
+551%
|
0
-98%
|
28
+13 167%
|
21
-25%
|
21
+0%
|
25
+17%
|
23
-6%
|
11
N/A
|
7
N/A
|
133
+1 721%
|
|
| Total Liabilities & Equity |
1
N/A
|
10
+677%
|
5
-49%
|
12
+143%
|
22
+76%
|
6
-73%
|
43
+642%
|
70
+64%
|
36
-49%
|
44
+21%
|
80
+83%
|
33
-58%
|
21
-37%
|
151
+618%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
1
|
1
|
1
|
3
|
3
|
4
|
6
|
9
|
9
|
1
|
10
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
1
|
0
|
0
|
0
|
0
|
|